Paul J. Shami
Rating: 5.0 of 5
( out of 64 reviews )

Paul J. Shami, MD

Languages spoken: English, French, Arabic

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
801-585-2626
Get Directions

  • Languages Spoken: English, French, Arabic

    Dr. Paul Shami is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah and is a Member and Clinical Investigator at the University’s Huntsman Cancer Institute (HCI). Dr. Shami also holds an Adjunct appointment as a Professor of Molecular Pharmaceutics at the University of Utah. He is Board Certified in Hematology and Medical Oncology. He started at the University of Utah in 1997. Dr. Shami oversees leukemia clinical trials at Huntsman Cancer Institute. His research also includes different strategies in drug discovery and drug development. Because of his expertise in the treatment of blood cancers, he serves or has served on the Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia and Myelodysplastic Syndrome panels of the National Cancer Center Network (NCCN).

    To schedule an appointment New Patients: 801-587-4630 Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Specialties

    Patient Rating

    Rating: 5.0 out of 5
    5.0 /5
    ( out of 64 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Paul Shami is the best! He and his team are highly skilled and knowledgeable care-givers who have been part of my life for the past 6 years. I want to thank them for the incredible level of medical care they have given me. They work long hours and deal with people in such a fragile state. I can't thank them enough for all they have done to help me beat cancer!

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    I wish I get my tests results

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Excellent Dr. that listens carefully and explains issues.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Going into his exam room he was already up to speed on my condition and ready to give me answers. He spent as much time with my wife and I as we needed with out rushing us out.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    He was very patient and thorough.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Shami is the best and most knowledgeable.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Shami is one of the all time best medical professionals I've dealt with. I'm so grateful for his expertise, intuitive skills and kindness he always shows to me.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Shami is a dedicated professional and always has your best interest as his goal in treating you.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    very good at giving us great options while also outlining the risks.

  • Languages Spoken: English, French, Arabic

    Dr. Paul Shami is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah and is a Member and Clinical Investigator at the University’s Huntsman Cancer Institute (HCI). Dr. Shami also holds an Adjunct appointment as a Professor of Molecular Pharmaceutics at the University of Utah. He is Board Certified in Hematology and Medical Oncology. He started at the University of Utah in 1997. Dr. Shami oversees leukemia clinical trials at Huntsman Cancer Institute. His research also includes different strategies in drug discovery and drug development. Because of his expertise in the treatment of blood cancers, he serves or has served on the Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia and Myelodysplastic Syndrome panels of the National Cancer Center Network (NCCN).

    To schedule an appointment New Patients: 801-587-4630 Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Academic Divisions Hematology & Hematologic Malignancies

    Education history

    Undergraduate Chemistry - American University of Beirut B.S.
    Professional Medical Medicine - American University of Beirut M.D.
    Internship Internal Medicine - Duke University Medical Center Intern
    Residency Internal Medicine - Duke University Medical Center Resident
    Fellowship Hematology/Oncology - Duke University Medical Center Fellow

    Selected Publications

    Journal Article

    1. Sorror ML, Storer BE, Fathi AT, Brunner AM, Gerds AT, Sekeres MA, Mukherjee S, Medeiros BC, Wang ES, Vachhani P, Shami PJ, Peña E, Elsawy M, Adekola KUA, Luger S, Baer MR, Rizzieri D, Wildes T, Koprivnikar J, Smith J, Garrison M, Kojouri K, Leisenring WM, Onstad L, Nyland JE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum F, Estey E (2021). Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. Blood, (Read full publication)
    2. Sorror ML, Storer BE, Fathi AT, Brunner A, Gerds AT, Sekeres MA, Mukherjee S, Medeiros BC, Wang ES, Vachhani P, Shami PJ, Peña E, Elsawy M, Adekola K, Luger S, Baer MR, Rizzieri D, Wildes TM, Koprivnikar J, Smith J, Garrison M, Kojouri K, Leisenring W, Onstad L, Nyland JE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey E (2021). Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood, 138(5), 387-400. (Read full publication)
    3. Narayanan S, Shami P (2012). Treatment of acute lymphoblastic leukemia in adults. Critical reviews in oncology/hematology, 81(1), 94-102. (Read full publication)
    4. Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi (2015). REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. British journal of haematology, 168(6), 796-805. (Read full publication)
    5. Wang ES, Aplenc R, Chirnomas D, Dugan M, Fazal S, Iyer S, Lin TL, Nand S, Pierce KJ, Shami PJ, Vermette JJ, Abboud C (2020). Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma, 61(8), 1965-1973. (Read full publication)
    6. Liu J, Malavya S, Wang X, Saavedra JE, Keefer LK, Tokar E, Qu W, Waalkes MP, Shami P (2009). Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells. Genomics, 94(1), 32-8. (Read full publication)
    7. Maciag AE, Nandurdikar RS, Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Shiao YH, Anderson LM, Keefer LK, Saavedra J (2011). Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs. Journal of medicinal chemistry, 54(22), 7751-8. (Read full publication)
    8. Saade M, Salamoun W, Tueni E, Shami P (1999). Who should be screened for hereditary breast cancer and what should be done with the information?. Le Journal medical libanais. The Lebanese medical journal, 47(5), 281-3. (Read full publication)
    9. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl (2010). Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. Journal of clinical oncology, 28(4), 549-55. (Read full publication)
    10. Kantarjian HM, Erba HP, Claxton D, Arellano M, Craig M, Douer D, Gabrilove J, Lyons R, Kovascovics T, Maris M, Petersdorf S, Shami PJ, Yaeger A, Eckert S, Abichandani R, Faderl S, On behalf of the CLASSIC II Investigator (2010). Phase II Study of Clofarabine Induction and Consolidation Therapy In Previously Untreated Older Adults With Acute Myelogenous Leukemia for Whom Conventional Induction Chemotherapy is Unlikely to be of Benefit Due to Unfavorable Baseline Risk Factors. Journal of clinical oncology, 28, 549-555.
    11. Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami P (2010). JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. The Journal of pharmacy and pharmacology, 62(1), 145-51. (Read full publication)
    12. Kaur I, Terrazas M, Kosak KM, Kern SE, Boucher KM, Shami P (2013). Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles. The Journal of pharmacy and pharmacology, 65(9), 1329-36. (Read full publication)
    13. Kiziltepe T, Anderson KC, Kutock JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami P (2010). JS-K has Potent Anti-Angiogenic Activity In Vitro and Inhibits Tumor Angiogenesis in a Multiple Myeloma Model In Vivo. The Journal of pharmacy and pharmacology, 62, 145-151.
    14. Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM, Keefer L (2011). The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species. The Journal of pharmacology and experimental therapeutics, 336(2), 313-20. (Read full publication)
    15. Shami PJ, Maciag AE, Eddington JK, Udupi V, Kosak KM, Saavedra JE, Keefer L (2009). JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C). Leukemia research, 33(11), 1525-9. (Read full publication)
    16. Rudrapatna VK, Morley K, Boucher KM, Pierson AS, Shull CT, Kushner JP, Shami P (2015). Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy. Leukemia research, 39(8), 835-9. (Read full publication)
    17. Willis C, Menon J, Unni S, Au T, Yoo M, Biskupiak J, Brixner D, Ndife B, Joseph G, Bonifacio G, Stein E, Tantravahi S, Shami PJ, Kovacsovics T, Stenehjem (2019). Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center. Leukemia research, 87, 106262. (Read full publication)
    18. Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, O'Hare T, Deininger M (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991. (Read full publication)
    19. Ciaccia D, Quigley RL, Shami PJ, Grant J (1994). A case of retrograde jejunoduodenal intussusception caused by a feeding gastrostomy tube. Nutrition in clinical practice, 9(1), 18-21. (Read full publication)
    20. Shami PJ, Crews (1995). Megaloblastic cytopenia in an AIDS patient treated with trimethoprim-sulfamethoxazole. North Carolina medical journal, 56(12), 602-4. (Read full publication)
    21. Kaur I, Kosak KM, Terrazas M, Herron JN, Kern SE, Boucher KM, Shami P (2015). Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K. Pharmaceutical research, 32(4), 1395-406. (Read full publication)
    22. Nandurdikar RS, Maciag AE, Holland RJ, Cao Z, Shami PJ, Anderson LM, Keefer LK, Saavedra J (2012). Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs. Bioorganic & medicinal chemistry, 20(9), 3094-9. (Read full publication)
    23. Weidensteiner C, Reichardt W, Shami PJ, Saavedra JE, Keefer LK, Baumer B, Werres A, Jasinski R, Osterberg N, Weyerbrock (2013). Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. Nitric oxide, 30, 17-25. (Read full publication)
    24. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami P (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC cancer, 21(1), 510. (Read full publication)
    25. Zhang R, Yang J, Zhou Y, Shami PJ, Kope'ek (2016). N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia. Macromolecular bioscience, 16(1), 121-8. (Read full publication)
    26. O'Brien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Pinilla-Ibarz J, Radich JP, Shah Md NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Wetzler M, National Comprehensive Cancer Network (2009). NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network, 7(9), 984-1023. (Read full publication)
    27. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P, National Comprehensive Cancer Network (2011). NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network, 9(1), 30-56. (Read full publication)
    28. O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ, Smith BD, Snyder DS, Sundar HM, Talpaz M, Wetzler (2011). NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network, 9 Suppl 2, S1-25. (Read full publication)
    29. O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, National Comprehensive Cancer Network (2011). Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network, 9(3), 280-317. (Read full publication)
    30. O'Brien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ, Devine S, Fathi AT, Gotlib J, Jagasia M, Moore JO, Pinilla-Ibarz J, Radich JP, Reddy VV, Shah NP, Shami PJ, Smith BD, Snyder DS, Wetzler M, Yunus F, National Comprehensive Cancer Network (2012). Chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network, 10(1), 64-110. (Read full publication)
    31. Shami P (2012). How to choose frontline therapy for chronic myelogenous leukemia: so many drugs, not so many patients. Journal of the National Comprehensive Cancer Network, 10(1), 112-8; quiz 119. (Read full publication)
    32. O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory K (2012). NCCN Clinical Practice Guidelines Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network, 10(8), 984-1021. (Read full publication)
    33. Slomowitz SJ, Shami P (2012). Management of extramedullary leukemia as a presentation of acute myeloid leukemia. Journal of the National Comprehensive Cancer Network, 10(9), 1165-9. (Read full publication)
    34. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma (2013). Myelodysplastic syndromes: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 11(7), 838-74. (Read full publication)
    35. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M, National Comprehensive Cancer Network (2013). Acute myeloid leukemia, version 2.2013. Journal of the National Comprehensive Cancer Network, 11(9), 1047-55. (Read full publication)
    36. Stenehjem DD, Albright F, Kuo KL, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner D (2014). Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database. Journal of the National Comprehensive Cancer Network, 12(8), 1113-21. (Read full publication)
    37. Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C, National comprehensive cancer network (2015). Myelodysplastic syndromes, version 2.2015. Journal of the National Comprehensive Cancer Network, 13(3), 261-72. (Read full publication)
    38. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM, OCN., Hammond L, Ogba (2019). Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17(6), 721-749. (Read full publication)
    39. Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman M (2021). NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal of the National Comprehensive Cancer Network, 19(1), 16-27. (Read full publication)
    40. Wang J, Li L, Yang J, Clair PM, Glenn MJ, Stephens DM, Radford DC, Kosak KM, Deininger MW, Shami PJ, Kope'ek (2019). Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine. Nanomedicine, 16, 217-225. (Read full publication)
    41. Edes K, Cassidy P, Shami PJ, Moos P (2010). JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1. PloS one, 5(1), e8786. (Read full publication)
    42. Uckun FM, Watts J, Mims AS, Patel P, Wang E, Shami PJ, Cull E, Lee C, Cogle CR, Lin T (2021). Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Cancers, 13(21), (Read full publication)
    43. Uckun FM, Lin TL, Mims AS, Patel P, Lee C, Shahidzadeh A, Shami PJ, Cull E, Cogle CR, Watts (2021). A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Cancers, 13(16), (Read full publication)
    44. Maciag AE, Holland RJ, Saavedra JE, Chakrapani H, Shami PJ, Keefer L (2012). Thiol Modification By Pharmacologically Active Agents of the Diazeniumdiolate Class. Forum on immunopathological diseases and therapeutics, 3(2), 91-95. (Read full publication)
    45. Chu TW, Zhang R, Yang J, Chao MP, Shami PJ, Kope'ek (2015). A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics, 5(8), 834-46. (Read full publication)
    46. Chu TW, Kosak KM, Shami PJ, Kope'ek (2014). Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells. Drug delivery and translational research, 4(5-6), 389-94. (Read full publication)
    47. Zhuo R, Kosak KM, Sankar S, Wiles ET, Sun Y, Zhang J, Ayello J, Prestwich GD, Shami PJ, Cairo MS, Lessnick SL, Luo (2014). Targeting Glutathione S-transferase M4 in Ewing sarcoma. Frontiers in pediatrics, 2, 83. (Read full publication)
    48. Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey E (2017). Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA oncology, 3(12), 1675-1682. (Read full publication)
    49. Erba HP, Becker PS, Shami PJ, Grunwald MR, Flesher DL, Zhu M, Rasmussen E, Henary HA, Anderson AA, Wang E (2019). Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood advances, 3(13), 1939-1949. (Read full publication)
    50. Sorror ML, Gooley TA, Storer BE, Gerds AT, Sekeres MA, Medeiros BC, Wang ES, Shami PJ, Adekola K, Luger S, Baer MR, Rizzieri DA, Wildes TM, Koprivnikar J, Smith J, Garrison M, Kojouri K, Schuler TA, Leisenring WM, Onstad LE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey E (2023). An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML. Blood, 141(3), 295-308. (Read full publication)
    51. Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler (2022). NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. Journal of the National Comprehensive Cancer Network, 20(2), 106-117. (Read full publication)
    52. Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman (2023). Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21(5), 503-513. (Read full publication)
    53. Shami P (2023). Development of JS-K, a First-in-Class Arylated Diazeniumdiolate, for the Treatment of Cancer. Critical reviews in oncogenesis, 28(1), 57-62. (Read full publication)
    54. Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, Zucenka A, De Botton S, Grove CS, Mannis GN, Papayannidis C, Perl AE, Issa GC, Aldoss I, Bajel A, Dickens DS, Kühn MWM, Mantzaris I, Raffoux E, Traer E, Amitai I, Döhner H, Greco C, Kovacsovics TJ, McMahon CM, Montesinos P, Pigneux A, Shami PJ, Stone RM, Wolach O, Harpel JG, Chudnovsky Y, Yu L, Bagley RG, Smith AR, Blachly J (2025). Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood, (Read full publication)
    55. Wuliji N, Jones SMW, Gooley TA, Gerds AT, Medeiros BC, Shami PJ, Galvin JP, Adekola KUA, Luger SM, Baer MR, Rizzieri DA, Wildes T, Wang ES, Sekeres MA, Mukherjee S, Smith J, Garrison M, Kojouri K, Appelbaum JS, Percival MM, Sandmaier BM, Lee SJ, Appelbaum F, Rouce RH, Sorror M (2025). Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Blood, (Read full publication)
    56. Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein E (2025). Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). Journal of clinical oncology, 43(1), 75-84. (Read full publication)
    57. McCarty RD, Trabert B, Kriebel D, Millar MM, Birmann BM, Grieshober L, Barnard ME, Collin LJ, Lawson-Michod KA, Gibson B, Sawatzki J, Carter M, Yoder V, Gilreath JA, Shami PJ, Doherty J (2024). Tattoos and Risk of Hematologic Cancer: A Population-Based Case-Control Study in Utah. Cancer medicine, 13(20), e70260. (Read full publication)
    58. Li J, Gambles MT, Jones B, Williams JA, Camp NJ, Shami PJ, Yang J, Kope'ek (2024). Human serum albumin-based drug-free macromolecular therapeutics induce apoptosis in chronic lymphocytic leukemia patient cells by crosslinking of CD20 and/or CD38 receptors. Drug delivery and translational research, 14(8), 2203-2215. (Read full publication)

    Review

    1. Shami PJ, Deininger (2012). Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia, 26(2), 214-24. (Read full publication)
    2. Zeng J, Yang N, Li XM, Shami PJ, Zhan (2010). 4'-O-Methylglycosylation of Curcumin by Beauveria bassiana. Natural product communications, 5, 77-80.

    Abstract

    1. Kosak KM, Saavedra JE, Keefer LK, Shami P (2009). A Pluronic® micelle formuation increases the stability of the novel anti-cancer nitric oxide prodrug JS-K. 643.
    2. Rudrapatna R, Kosak KM, Terrazas M, Kennedy TP, Shami P (2010). Development of Dithiocarbamate/Metal Complexes in Pluronic® micelles for the Treatment of Malignancies. 5526.
    3. Kaur I, Kosak KM, Saavedra JE, Keefer LK, Kern Se, Shami P (2010). Cellular uptake and stability studies of the nitric oxide-generating pro-drug JS-K. 2651.
    4. Maciag AE, Chakrapani H, Holland RJ, Morris JL, Shami PJ, Saavedra JE, Anderson LM, Keefer L (2010). Diazeniumdiolate-based nitric oxide-releasing prodrugs kill lung adenocarcinoma in cells in culture and in vivo through alterations in cellular redox balance leading to mitochondrially-mediated apoptosis. 4547.
    5. Rudrapatna RK, Morley K, Kushner JP, Pierson AS, Shull CT, Shami P (2013). Phase I Trial of Low-Dose Oral Clofarabine in Myelodysplastic Syndromes Patients Who Have Failed Frontline Therapy.

  • News & Podcasts

    Huntsman Cancer Institute News